RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Primary Ciliary Dyskinesia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
RNA sequencing significantly improves HYDIN diagnosis and defines the effects of common deletions in primary ciliary dyskinesia.
Jaramillo Oquendo Carolina et al., European journal of human genetics : EJHG (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42888219/
- 2.
Conditionally Reprogrammed Patient-Derived Nasal Epithelial Cell Cultures for In Vitro Diagnostics and Pharmacological Profiling in Primary Ciliary Dyskinesia
Ruth Maria Urbantat et al., Cells (15 October 2026)
https://doi.org/10.3390/cells15201871
- 3.
In situ structure of the human ciliary transition zone links linker defects to primary ciliary dyskinesia.
Zhou Haixia et al., Science (New York, N.Y.) (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42721274/
- 4.
Diffuse bronchiolitis and atelectasis as early features of primary ciliary dyskinesia in children: a genotype–phenotype study
Shapaguli Aizezi et al., Orphanet Journal of Rare Diseases (13 October 2026)
https://doi.org/10.1186/s13023-026-04660-4
- 5.
Targeted mRNA restoration of ciliary function in DNAI1-related primary ciliary dyskinesia: ex vivo rescue in patient-derived nasal spheroids—a proof-of-concept study
Caroline Marie Torp Nygaard et al., European journal of medical research (13 October 2026)
https://doi.org/10.1186/s40001-026-05313-9
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
NCT05737485 · Completed · Phase 1 · ReCode Therapeutics
Ages 18 to 75
https://clinicaltrials.gov/study/NCT05737485
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare genetic condition caused by defective cilia function, leading to chronic respiratory infections, bronchiectasis, and fertility problems. Kartagener syndrome (with situs inversus) is a subset. It is significantly underdiagnosed. No disease-modifying therapies currently exist, but several are in trials.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder affecting ~1:7500 individuals characterised by recurrent chronic respiratory infections, bronchiectasis, laterality defects, and infertility. While at least 60 PCD-causing genes are reported, approximately 30% of patients remain without a confirmed molecular diagnosis. PCD caused by biallelic HYDIN variants is difficult to diagnose due to a 98% homologous pseudogene (HYDIN2). Additionally, functional ciliary diagnostic testing can be inconclusive due to the lack of discernible HYDIN ciliary ultrastructure defects by electron microscopy. Our aim was to diagnose genetically unresolved PCD patients with strong clinical suspicion of HYDIN defects using RNA sequencing (RNA-seq). RNA-seq was performed on total RNA extracted from patients' nasal epithelium cultured for 21 days at the air-liquid interface. Splicing abnormalities were detected using rMATS and genome-aligned reads were manually inspected using Integrative Genome Viewer. Thirteen individuals had strong clinical suspicion of PCD, normal TEM and inconclusive genetics: 11/13 had a single pathogenic or likely pathogenic variant in HYDIN, 1/13 had no variants, and 1/13 required clarification of variant origin (HYDIN vs HYDIN2). RNA-seq resolved 11/13 (85%) of cases. The same complex pathogenic aberrant splicing events were seen in seven unrelated patients. This abnormal splice pattern was caused by a large 10-kilobase deletion spanning intron 17 to intron 18. RNA-seq increases the diagnostic yield for patients with suspected PCD and has exposed a HYDIN 'hotspot' variant, increasing the observed prevalence of HYDIN-related cases within our genetically diagnosed cohort. Routine PCD genomics testing will now incorporate investigation of this genetic region of HYDIN.
Common Questions
What is Primary Ciliary Dyskinesia?
Primary ciliary dyskinesia is a rare genetic condition caused by defective cilia function, leading to chronic respiratory infections, bronchiectasis, and fertility problems. Kartagener syndrome (with situs inversus) is a subset. It is significantly underdiagnosed. No disease-modifying therapies currently exist, but several are in trials.
How many clinical trials are available for Primary Ciliary Dyskinesia?
RareWays currently indexes 22 clinical trials for Primary Ciliary Dyskinesia, of which 5 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Primary Ciliary Dyskinesia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Primary Ciliary Dyskinesia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.